Fortunately, you’re not alone. With BridgeView as your solutions partner, you receive the strategic acumen, best-in-class SaaS platforms, and comprehensive services needed to plan, launch, scale, and operationalize with complete confidence. We are passionate about delivering actionable data ahead of your competition, ensuring faster, better outcomes for HCPs and patients.
Transformation + Acceleration = Success
BridgeView implements and manages a broad set of business-critical services, from business applications to information management. Our Program Management Office [link to Services] orchestrates every aspect of your technology ecosystem, allowing your organization to spend less time on IT and more time serving customers and patients.
BridgeView configures its cloud-native applications to accelerate the speed and precision of customer decision making. We offer innovative platform for commercial data management, analytics and reporting of aggregated and tokenized specialty and third-party patient data, as well as management of complex projects and portfolios.
Chances are, you’ve worked with a technology provider that scopes big and delivers small. Many providers throw droves of junior staff at projects instead of assigning true domain experts. With BridgeView, customers get the best, most qualified team for the duration of every project.
The BridgeView team has worked the trenches of biotech startups and walked the halls of Top 5 pharmaceutical companies. Our knowledge, expertise, and operational excellence have been cultivated over hundreds of successful projects, helping us serve life sciences companies at any life cycle stage.
Harmonize disparate systems to achieve mutual success. Rationalize system integrations, eliminate redundancies, and migrate data and users with minimal friction.
With few treatment options for patients, hematologists look to pipeline agents such as Johnson & Johnson’s nipocalimab and Novartis’ ianalumab to improve patient outcomes, according
US retinal specialists identify 4D Molecular Therapeutics’ 4D-150, Adverum Biotechnologies’ Ixo-vec, and Johnson & Johnson’s JNJ-1887 as most likely pipeline candidates for prescription if approved.
Spherix Global Insights recently delved into the efficacy, patient quality of life, and symptom management of adalimumab vs secukinumab. Managing hidradenitis suppurativa (HS) effectively remains
Takeda’s resurrection of the once-rejected Eohilia appears to be paying off, with a survey of physicians finding the launch is in line with the rollout of Dupixent
Impacts of Eohilia’s short-term 12-week label are still unfolding, but prescribers express interest in continuing consecutive treatment courses. EXTON, PA., July 18, 2024 – In
Epileptologists and general neurologists have different approaches to treating people with refractory epilepsy, according to the Market Dynamix: Adult Refractory Epilepsy (US) study conducted by
